Moluzen Molnupiravir 200 mg
Price range: $60.00 through $180.00
| Quantity Value | Price | Quantity | Add To Cart |
|---|---|---|---|
| 160 Capsules | $180.00 |
|
|
| 40 Capsules | $60.00 |
|
|
| 80 Capsules | $100.00 |
|
SKU : N/A
Category : Viral Care
Moluzen Molnupiravir 200 mg is an oral antiviral medicine used to treat mild to moderate COVID-19 in adults at risk of severe illness by reducing viral replication. It is most effective when started early in the course of infection under medical supervision
Moluzen Molnupiravir 200 mg
Moluzen Molnupiravir 200 mg is a prescription antiviral medication formulated to help treat mild to moderate COVID-19 infection in adults who are at increased risk of progressing to severe disease, hospitalization, or death. Its active ingredient, molnupiravir, belongs to a class of drugs called nucleoside analogues that disrupt the replication process of the SARS-CoV-2 virus — the virus responsible for COVID-19. Moluzen is designed to be taken orally, offering convenience and effectiveness as an outpatient therapy when initiated early in the course of illness.
How Molnupiravir Works
Molnupiravir is a prodrug, meaning it is converted inside the body into its active form — N-hydroxycytidine (NHC). This active compound becomes incorporated into the viral RNA by the SARS-CoV-2 enzyme RNA-dependent RNA polymerase (RdRp). Once incorporated, it introduces a large number of errors into the newly synthesized viral RNA during replication. These errors lead to what scientists call “error catastrophe”, rendering the virus unable to produce viable copies of itself. The result is a reduction in viral replication and viral load, giving the immune system a better chance to clear the infection.
This mode of action does not directly kill the virus but rather prevents it from multiplying effectively, slowing disease progression and reducing severity.
Indications and Uses
Moluzen Molnupiravir 200 mg is indicated for:
-
Treatment of mild to moderate COVID-19 in adults
-
Patients who have tested positive for SARS-CoV-2
-
Individuals at high risk for severe COVID-19 due to factors such as advanced age, diabetes, cardiovascular disease, obesity, or compromised immunity
It is important to note that this medicine is not authorized for use in patients who are hospitalized with severe COVID-19, and it is not intended for prevention (prophylaxis) of infection.
Recommended Dosage and Administration
The typical administration of Moluzen Molnupiravir 200 mg for adults involves:
-
800 mg (four capsules of 200 mg) taken twice daily (every 12 hours)
-
Duration: 5 days
-
Treatment should begin within five days of symptom onset to achieve the best possible outcomes
The capsules should be swallowed whole with water and may be taken with or without food. It is crucial to complete the full prescribed course, even if symptoms improve before the 5-day period ends, to ensure effective suppression of viral replication.
Benefits of Moluzen Molnupiravir Treatment
When used appropriately and early in the disease course, Moluzen Molnupiravir 200 mg may:
-
Reduce the risk of progression to severe disease
-
Lower the chance of hospitalization or death in high-risk individuals
-
Decrease viral load more rapidly than the body alone
-
Offer a convenient oral therapy versus intravenous antiviral options
Because it can be taken at home, molnupiravir provides a practical outpatient option for eligible patients under close medical guidance.
Side Effects and Safety Information
Like all medications, Moluzen Molnupiravir 200 mg may cause side effects in some individuals. Commonly reported effects include:
-
Nausea
-
Diarrhea
-
Headache
-
Dizziness
These side effects are generally mild and transient. Patients should monitor their symptoms and seek medical advice if adverse reactions are severe, persistent, or concerning.
Precautions and Considerations
Before starting Moluzen Molnupiravir, patients should inform their healthcare provider if they:
-
Are pregnant or breastfeeding — molnupiravir is generally not recommended during pregnancy due to potential risks; effective contraception is advised for those of reproductive potential during treatment and for a period after.
-
Have known allergies to molnupiravir or any capsule components.
-
Are taking any other medications, including prescription and over-the-counter drugs, as interactions may occur.
Moluzen is not authorized for use in children due to lack of approved safety data in pediatric populations. Dose adjustments are also not generally recommended outside specific medical contexts like severe kidney or liver impairment unless under expert supervision.
Storage and Handling
Moluzen Molnupiravir 200 mg capsules should be stored in a cool, dry place away from direct sunlight and moisture. Keep the medicine out of reach of children and pets.
For authoritative, medically reviewed information on molnupiravir and its use in treating COVID-19, visit:
https://medlineplus.gov/druginfo/meds/a621008.html
| Pack Size |
160 Capsules ,40 Capsules ,80 Capsules |
|---|
Related products
